TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03496805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGE
Description: The patients will take 4 capsules by mouth BID (twice daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will take 4 capsules by mouth BID (twice daily).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADT
Description: Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
Study: NCT01008774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Caps
Description: Scalp cooling procedures
Study: NCT03800680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Management Package (DMP)
Description: M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Management Package (DMP)
Description: M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-POWER Rewards
Description: A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
Study: NCT00484926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: stopping clopidogrel at 1 year after DES

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study: NCT03908554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WORKPLACE HEALTH PROMOTION PROGRAM
Description: WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
Study: NCT02761096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
Study: NCT06546215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
Study: NCT01443234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxIGen
Description: Internet-based intervention with 12 sessions over 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OxIGen: control version
Description: A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
Study: NCT00568737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: Drotrecogin Alfa (activated)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT03365518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy
Description: The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
Study: NCT00437060

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies
Study: NCT04259632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: daily eating window restricted to 8 hours

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction (CR)
Description: 15% daily caloric deficient
Study: NCT03361306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Experimental
Study: NCT02015013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 microgram/kg daily for 5 days, Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
Study: NCT04482309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion
Study: NCT03969563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: 8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: 8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
Study: NCT04437342

Intervention type: OTHER
Intervention: PHQ-9 (Patient Health Questionnaire) Depression Scale
Description: 9 question questionnaire for assessment of depression

Intervention type: OTHER
Intervention: GAD-7 (General Anxiety Disorder) scale
Description: 7 question questionnaire for assessment of General Anxiety Disorder

Intervention type: OTHER
Intervention: 38 questions questionnaire
Description: 38 questions questionnaire

Intervention type: OTHER
Intervention: EPDS (Edinburgh Postnatal Depression Scale)
Description: 10 questions scale for detection of postpartum depression
Study: NCT01564433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: Electromechanical gait trainer
Description: The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convetional control treatment
Description: The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
Study: NCT04879420

Intervention type: DRUG
Intervention: Teriparatide
Description: Teriparatide dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: Risedronate
Description: Risedronate dispensing claim is used as the exposure group.
Study: NCT01607775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a PEEK-cage
Description: A commercially avaliable cuboid cervical cage will be implantet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA-cage
Description: The in-house produced cervical cage will be implanted
Study: NCT03603756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: a novel anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: a novel anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a VEGFR-2 tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a VEGFR-2 tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection
Description: cytotoxic agent that binds to topoisomerase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: cytotoxic agent that prevent depolymerization of cellular microtubules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: cytotoxic agent that cross-links and denatures strands of DNA
Study: NCT01596647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: dovitinib, 5 days on / 2 days off dose schedule
Study: NCT00084084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Description: 0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Description: 0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
Study: NCT04541719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled remifentanil analgesia
Description: Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural analgesia
Description: Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
Study: NCT02503579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training
Description: physical activity program, 30 minutes
Study: NCT02672553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDWARDS INTUITY Valve System, Model 8300A
Description: To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stented Aortic Bioprostheses
Description: In comparison to control valves available on the market undergoing FS-AVR
Study: NCT04641936

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required
Study: NCT04489407

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote Photoplethysmography (rPPG) vital sign acquisition
Description: Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Photoplethysmography (rPPG) vital sign acquisition
Description: Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
Study: NCT02184728

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: End-tidal CO2(portable capnometer)
Description: End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
Study: NCT01946165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1,000 mg by mouth daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1,000 mg by mouth daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth once daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth once daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
Study: NCT00655642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: 12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Study: NCT04367883

Intervention type: DRUG
Intervention: Antihistamine
Description: No intervention is performed. We propose an observational study.

Intervention type: DRUG
Intervention: Antihistamine
Description: No intervention is performed. We propose an observational study.

Intervention type: DRUG
Intervention: Amantadine
Description: No intervention is performed. We propose an observational study

Intervention type: DRUG
Intervention: Amantadine
Description: No intervention is performed. We propose an observational study

Intervention type: DRUG
Intervention: ACEI
Description: No intervention is performed. We propose an observational study.

Intervention type: DRUG
Intervention: ARB
Description: No intervention is performed. We propose an observational study.

Intervention type: OTHER
Intervention: Influenza vaccine and COVID
Description: No intervention is performed. We propose an observational study.
Study: NCT02872909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulight (Ambicare Health)
Description: battery-operated low irradiance red light LED (skin cancer plaster)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulight (Ambicare Health)
Description: battery-operated low irradiance red light LED (skin cancer plaster)
Study: NCT01912859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/physical activity intervention
Description: Nutrition/physical activity intervention
Study: NCT01761643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SoC + iTab
Description: Text messaging reminders to improve adherence to PrEP
Study: NCT03568383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (DLM)
Description: Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
Study: NCT04252963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUCOLASE tablet (streptokinase • streptodornase)
Description: streptokinase • streptodornase 5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of MUCOLASE tablet
Study: NCT05948137

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDOPA PET/CT
Description: Nuclear medicine imaging modalities
Study: NCT02087670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: controlled, supervised exercise protocol
Description: exercise program within a cardiac rehabilitation program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise protocol no supervised
Description: Exercise program at the community
Study: NCT03128853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 and DCI Mini Sensor